REFRACTORY HEPATOBLASTOMA
Clinical trials for REFRACTORY HEPATOBLASTOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HEPATOBLASTOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HEPATOBLASTOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with Hard-to-Treat cancers: Two-Drug attack on tumors
Disease control Recruiting nowThis study is for children and young adults whose solid tumors have come back or not gone away. It tests two different drug pairs that damage cancer cell DNA to kill the tumor. The goal is to find the best dose and see if the treatment can shrink or stop the cancer.
Matched conditions: REFRACTORY HEPATOBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for young cancer patients: experimental drug targets tough tumors
Disease control Recruiting nowThis study tests a drug called tegavivint in children, teens, and young adults (ages 1 to 30) whose solid tumors have returned or are not responding to standard treatments. The drug works by blocking a key signal that tells cancer cells to grow. The trial aims to find the safest …
Matched conditions: REFRACTORY HEPATOBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 06, 2026 16:01 UTC
-
New registry aims to unlock secrets of rare childhood liver cancer
Knowledge-focused Recruiting nowThis study is creating a registry to gather medical information, images, and tumor samples from up to 500 people of any age whose liver cancer (hepatoblastoma) has come back or not responded to treatment. The goal is to better understand the disease and help researchers develop b…
Matched conditions: REFRACTORY HEPATOBLASTOMA
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC